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Strain Elastography for Noninvasive Assessment of Liver Fibrosis: A Prospective Study 
with Histological Comparison 
Abstract 
Aim: To prospectively evaluate the diagnostic performance of strain elastography (SE) for the 
assessment of liver fibrosis in patients with chronic liver disease using Ishak [0-6] histology stage 
as a reference standard. 
Materials and Methods: Ninety-eight consecutive patients with suspected chronic liver disease 
scheduled for liver biopsy (n=78) or histologically confirmed cirrhosis (n=20) were enrolled. Liver 
Fibrosis (LF) Index calculated by SE, liver stiffness by transient elastography (TE), and serum 
fibrosis markers (aspartate aminotransferase-to-platelet ratio index [APRI], King’s Score) were 
measured. Spearman’s correlation coefficient between the LF Index, liver stiffness, serum fibrosis 
markers and fibrosis stage were calculated and compared using areas under the receiver-
operating characteristics (AUROCs) curves. 
Results: Among 73 patients who underwent SE, there was weak correlation between fibrosis 
stage and the LF Index (Spearman’s: ρ=0.385 for Ishak score; P=0.001). Among 52 patients who 
underwent SE and TE, the AUROC values using LF Index, TE, APRI, and King’s Score for 
diagnosing significant fibrosis (Ishak score ≥3) were 0.79, 0.87, 0.86, and 0.85, respectively 
(P<0.0001); and 0.83, 0.94, 0.92, and 0.92 (P<0.0001), respectively for diagnosing severe 
fibrosis/cirrhosis (Ishak score ≥5). When comparing the diagnostic performance using LF index, 
TE, APRI and King’s score, TE shows a significantly higher AUROC value than LF index in 
detecting severe fibrosis (P=0.0149). 
Conclusion: The diagnostic performance of LF Index calculated by SE was not statistically 
significantly different to the other non-invasive tests for the assessment of significant liver fibrosis 
but inferior to TE for the assessment of severe fibrosis/cirrhosis.  
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Introduction 
Assessment of the degree of liver fibrosis is important in patients with chronic liver disease to 
estimate prognosis, to determine surveillance intervals and guide treatment decisions. At present, 
liver biopsy is used as the reference standard for the assessment of liver fibrosis. However, it is 
an invasive method associated with patient discomfort and, on occasion, with serious 
complications (1). In addition, the accuracy of liver biopsy is limited due to significant intra- and 
inter-observer variability and sampling errors (2–4).  
Non-invasive ultrasound-based methods for the assessment of liver fibrosis in patients with 
chronic liver disease have been widely adopted in recent years using a measure of liver 
‘stiffness’, termed elastography. A variety of elastography methods are available for the 
assessment of liver fibrosis. Transient elastography (TE) and shear wave elastography (SWE) 
methods, including point SWE (pSWE) and multidimensional SWE (2D-SWE and 3D-SWE), all 
measure the propagation speed of a shear wave transmitted from a transducer through the liver 
(5). As hepatic fibrosis progresses, the propagation speed increases. The shear waves can be 
generated by an external push (TE), by ultrasound radiation force enabling a single measurement 
(pSWE) or by an image (2D-SWE and 3D-SWE).  
In contrast to the above elastography methods, strain elastography (SE) diagnoses hepatic 
fibrosis using the tissue deformation (strain) within the liver induced by an external compression 
(6,7). From transducer-induced deformation of tissues measured between consecutive echo 
signal frames, a colour-coded map of the strain distribution (elastogram) is overlaid on the B-
mode image. The extent of the tissue deformability of the tissue (strain) is related to its stiffness. 
SE provides a qualitative measurement of higher or lower stiffness, which is displayed with color-
coded mapping (6). Quantitative stiffness values can be obtained by converting the colour 
mapping scale to a numerical scale using various measurements generated by the elastography 
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module (8). The first commercial application of SE was developed by Hitachi Medical Systems 
(Tokyo, Japan) and given the real time modality of this technique it is frequently called real-time 
tissue elastography (RTE). Several studies have demonstrated the usefulness of RTE in the 
assessment of liver fibrosis (9–17). Despite promising results for the prediction of liver fibrosis in 
Asian patients, several studies have shown its performance in European patients to be inferior to 
TE (11,18). In view of this, guidelines recommend that further research regarding the use of SE in 
the assessment of liver fibrosis is required (19). 
The aim of this study was to evaluate the diagnostic performance of SE, using RTE, for the 
assessment of liver fibrosis in multi-ethnic, urban patients in a European setting, with chronic liver 
disease using histology fibrosis staging (Ishak) as a reference standard.  
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Methods 
Study population 
We prospectively enrolled 98 adult patients with suspected chronic liver disease scheduled for 
liver biopsy or with confirmed (histological or clinical) cirrhosis in our institution over a one-year 
period (between October 2011 and October 2012). Inclusion criteria were age >18 years; 
suspected chronic liver disease based on clinical history, serum biochemistry, prior imaging or 
prior liver biopsy; referral for ultrasound and liver biopsy for staging and grading of fibrosis and/or 
cirrhosis. The cohort of patients with confirmed cirrhosis on imaging were not required to undergo 
further liver biopsy. Exclusion criteria included liver transplantation within the last six months, 
suspected or known acute liver disease, and pregnancy. The study was performed following 
ethical approval (study and registration number: 11/LO/0552, KCH11-143) and informed consent 
was obtained from all participants. 
Strain elastography 
B-mode standard ultrasonography and SE measurements were performed prior to liver biopsy 
using a Hitachi HI VISION Preirus machine (Hitachi Medical Systems, Tokyo, Japan), with a 
EUP-L52 linear (3–8 MHz) transducer. Subjects were examined in a supine position with the right 
arm extended over the head by three trained observers (SV, JJ, and OB). The transducer was 
placed in a right intercostal space and angled manually towards the heart (external compression 
source) without exerting any manual pressure with the transducer. The rectangular region of 
interest (ROI) of the hepatic parenchyma was 25 x 25 mm with the top of the ROI positioned 
approximately 10 mm inside the capsule of the liver to avoid multiple reflections and any large 
vessels (20)[Figure 1]. 
The elastography module is based on real-time analysis of tissue displacement (strain) induced 
by dynamic cardiac movement of the ROI. A colour map is generated showing hard (blue), 
intermediate (green) and soft (red) tissue areas. The measurement area was chosen when the 
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colour-coded elastogram was stable with any vessel or rib shadows minimised and recorded for 5 
seconds. Patients were instructed to hold their breath (in a neutral phase) during imaging 
acquisition (at least 5 heart beats). The best image at negative peak strain on the strain graph 
was recorded when the image was subjectively most green and then most blue. The strain 
histogram was visualized, and analysis performed in the ROI. Image acquisition and strain 
histogram measurements were repeated a further two times. Digital images were stored at 
maximum quality and reviewed off-site by the ultrasound manufacturer. Image features were 
extracted from each elastography image (21). Multiple regression analyses were then performed 
with the following 9 image features: 1. mean of relative strain value, 2. standard deviation of 
relative strain value deviation; 3. ratio of blue area in the analysed region; 4. complexity of blue 
area; 5. Kurtosis of strain histogram; 6. Skewness of strain histogram; 7. entropy; 8. inverse 
difference moment; 9. angular second moment to calculate the Liver Fibrosis Index (LF Index) 
using a previously described formula (22). The LF Index equation using these 9 features was 
based on an equation adapted from Japanese patients with hepatitis C (12,23). The mean value 
of the three LF Index measurements was used as the result. A higher LF index indicates harder 
hepatic elasticity, and by inference more advanced liver fibrosis or cirrhosis. 
Transient elastography 
For logistical reasons, TE examinations (FibroScan®, Echosens, France)  could not be performed 
on the same day as the liver biopsy, however they were performed in all patients within three 
months of the liver biopsy using methods described previously (24), by experienced observers as 
part of routine clinical practice. Measurements were performed on the right lobe of the liver 
through the right intercostal spaces. The medians of 10 measurements were recorded and the 
results expressed in kilopascals.  
Serum fibrosis markers 
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Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase 
(GGT), total bilirubin, platelet count, international normalised ratio (INR), alkaline phosphatase 
(ALP) were measured on the same day as the SE and the AST-to-platelet ratio index (APRI) (25) 
and King’s Score (26) then calculated. The APRI index was calculated as: AST (/upper limit of 
normal range) x 100/platelet count (109/L) (25). The King’s Score was calculated as: age x AST x 
INR/platelet count (109/L) (26).  
Liver histology 
The histology specimens were taken on the same day following SE in the right lobe or from 
archived biopsy specimens in patients with documented cirrhosis. SE was performed before 
biopsy to avoid tissue disturbance due to the biopsy. All biopsies were performed percutaneously 
under ultrasound guidance using an 18-G Tru-Cut needle (Argon Medical Devices Inc., Athens, 
Texas). The biopsy specimens were fixed in formalin and embedded in paraffin according to 
standard procedures. All biopsy specimens were evaluated by a single experienced liver 
histopathologist (AQ) who was blinded to the patients’ clinical data and ultrasound 
measurements. Liver fibrosis stage was scored using the biopsy criteria described for the Ishak 
stage scoring systems (27).  
Statistical analyses 
Statistical analysis was performed using Statistical Packages for the Social Sciences (SPSS) for 
Windows (v22, IBM, Chicago) and MedCalc for windows, v17.6, All predictors for the stage of 
fibrosis (SE [using LF index], TE, King’s Score and APRI) are continuous variables and were 
therefore summarized as mean ± standard deviation or as medians and range. The diagnostic 
performances of these non-invasive tests for the prediction of fibrosis in each of the patients were 
then assessed by plotting the receiver-operator characteristic (ROC) curves. Optimal cut-off 
values were chosen to maximize the sum of the sensitivity and specificity using the Youden Index 
for different fibrosis thresholds: Ishak 0-2 vs 3-6 (Ishak ≥3), Ishak 0-4 vs 5-6 (Ishak ≥5). For this 
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study, significant fibrosis was defined as Ishak stages 3 and above and severe fibrosis/cirrhosis, 
now termed advanced stage liver disease (28) as Ishak stage 5 or above. Diagnostic accuracy 
was also evaluated by comparing the sensitivity, specificity, positive and negative predictive 
values based on these cut-off values. The 95% confidence intervals were determined for the non-
invasive markers and utilized when comparing the area under the ROC (AUROCs) curves. 
Differences between the AUROCs were compared by using a Delong test (29). Spearman’s 
Correlation coefficient was calculated to test for the relationship between Ishak liver fibrosis stage 
and the non-invasive tests (SE, TE, King’s Score and APRI). Weak, moderate, strong correlation 
were defined if Spearman’s correlation coefficient ρ<0.4; 0.4≤ρ<0.59, ρ≥0.60 respectively. All 
tests were two-sided and P <.05 signified a significant difference.  
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Results 
Patient characteristics  
Ninety-eight patients met the inclusion criteria and were enrolled in the study. Of these, 78 
patients underwent liver biopsy; a further 20 patients with a confirmed clinical diagnosis of 
cirrhosis underwent B-mode standard ultrasonography and SE without further liver biopsy. 
Relationship between LF Index, serum markers and liver biopsy histologic findings 
Of the 98 enrolled patients, SE measurements were successful in 97 patients (success rate 
98.98%). 24 patients were excluded from this analysis because of unreliable clinical assessment 
of cirrhosis on repeat ultrasound (n=6), no histology report due to inadequate samples (n=2), SE 
measurement that could not be analyzed (n=16). This left 73 patients suitable for analysis. Their 
characteristics are summarized in Table 1. The patient ethnicity of the study cohort are: 37.0% 
Caucasian (n=27), 31.5% African-Caribbean (n=23), 20.5% Asian (n=15), 8.2% other (n=6) and 
2.7% mixed (n=2). Most patients with chronic liver disease had hepatitis B (n=52/73, 71.2%). The 
proportion of patients with significant (Ishak stage ≥3) and severe fibrosis/cirrhosis (Ishak stage 
≥5) was 27.4% (n= 20/73) and 9.6% (n=7/73), respectively. The median (minimum, maximum 
value) LF index, APRI and King’s score for each Ishak fibrosis stage are listed in Table 2 and 
displayed as box and whisker plot in Figure 2.  There was weak significant correlation between 
fibrosis stage and the LF Index (Spearman’s ρ=0.385; P=0.001).  There were moderate 
significant correlations between fibrosis stage and serum markers (APRI: Spearman’s ρ=0.524, 
P<0.001; King’s score: Spearman’s ρ=0.582, P<0.001) 
Relationship between TE and liver fibrosis scores 
A further 21 patients were excluded from this analysis due to lack of TE measurements, leaving 
52 patients suitable for analysis. Their characteristics are summarized in Table 1. The TE 
measured in the study patients ranged from 3.3 KPa to 36.9.1KPa. The median (minimum, 
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maximum value) TE value for each Ishak fibrosis stage are listed in Table 2, Figure 2. There was 
strong significant correlation between fibrosis stage and the TE measurement (Spearman’s 
ρ=0.675; P=0.001).  
Diagnostic accuracy of LF index, TE and serum markers using Ishak histological scores.  
The accuracy of SE (using LF index), TE, APRI and King’s Score in predicting significant (Ishak 
≥3) and severe (Ishak ≥5) liver fibrosis are shown in Tables 3, Figure 3.  
The AUROCs of LF index, SE, TE, APRI and King’s Score for diagnosis of significant fibrosis did 
not differ significantly (P >0.05) (Figure 3a). Comparison of the AUROCs of SE (using LF index), 
TE, APRI and King’s Score for the diagnosis of severe fibrosis/cirrhosis showed that TE had 
significantly higher accuracy compared to SE (using LF index) P = 0.0149. No significant 
differences were detected when comparing AUROC between the other parameters (Figure 3b).  
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Discussion 
Recent interest in non-invasive evaluation of liver disease is related to the risk of complications 
associated with liver biopsy and technical limitations of the procedure (30). In view of this, various 
noninvasive methods have been developed to predict the presence of clinically significant 
fibrosis. In this study, we evaluated the use of LF Index calculated by SE in predicting the 
presence of significant liver fibrosis, using liver biopsy as a reference standard. The principle 
finding of this study was that LF index by SE was not a useful predicator of histologic fibrosis 
stages as determined by the Ishak scores. Secondary analyses showed that the diagnostic 
performance of SE in this heterogeneous population including predominant Caucasian and 
African-Caribbean patients was similar to other non-invasive tests for the assessment of 
significant liver fibrosis but inferior to TE for the assessment of severe fibrosis/cirrhosis in patients 
with suspected chronic liver disease.  
A number of studies have evaluated the diagnostic performance of SE using RTE for the 
assessment of liver fibrosis in patients with chronic liver disease. Since RTE is essentially a 
qualitative technique, various semi-quantitative methods have been developed to analyse the 
elastograms produced by SE (8). These include the elasticity index (14,31), the elasticity ratio 
(15,16,32) and the LF Index (12,21–23,33,34). The elastic ratio refers to the ratio of these values 
in the hepatic parenchyma to the values in a reference tissue such as intercostal muscles and 
intrahepatic venous vessels. The elastic index, elasticity score, and LF Index are all calculated by 
formulas including several descriptive statistics (e.g. mean, median, maximum) derived from 
quantified pixel data. In this study, the LF index was used as the analytic method of SE. It was 
the first quantitative method developed involving use of 9 parameters (21). A meta-analysis of 5 
studies (722 subjects) in 2014 showed significant heterogeneity when using the LF index for the 
assessment of significant fibrosis, thereby limiting an assessment of the overall accuracy of RTE. 
The authors reported that RTE showed limited potential as a substitute for TE in the assessment 
of liver fibrosis (35). A further meta-analysis in 2015 of 15 studies (1,626 subjects) reported that 
the overall accuracy of RTE was nearly identical to TE for the evaluation of significant fibrosis, but 
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less accurate for the evaluation of cirrhosis (36). The variable results reported with the different 
quantitative methods have therefore limited the clinical use of RTE (35). There are however 
conflicting results to the 2015 meta-analysis whereby RTE was shown to have a strong positive 
correlation with histologic liver fibrosis and high diagnostic accuracy in predicting significant and 
severe fibrosis (17,22,37). We postulate that the observed difference in diagnostic accuracy may 
be because prior studies were exclusively performed in East Asian populations where the body 
mass index is lower than in our study population, although this could not be analysed formally as 
body mass index from our study cohort was not collected at the time of the study.  
The two endpoints used in this study were significant fibrosis (Ishak stage 3 or greater), which is 
an indication for anti-viral treatment in patients with chronic hepatitis B and C; and severe 
fibrosis/cirrhosis (Ishak stage 5 or greater) which leads to closer monitoring of complications: 
portal hypertension, hepatic insufficiency and hepatocellular carcinoma (38). We used these liver 
fibrosis categories as they enable reliable identification of liver cirrhosis, as well as the ability to 
distinguish low risk of fibrosis (Ishak 0–2) from more advanced stages of liver fibrosis (Ishak 3–6). 
We evaluated the use of SE with liver histology using the 7-point Ishak staging systems which 
allows a more detailed description of advanced stage liver disease (stage 5 and 6) compared with 
the Metavir score. It has been argued that the gap between 3 (numerous septa without cirrhosis) 
and 4 (cirrhosis) in the Metavir score is too large and an additional level is required to differentiate 
between severe fibrosis and cirrhosis (39).  
The strength of this study is that it not only compares the diagnostic accuracy of SE with the 
reference standard, liver biopsy, but also with TE and serum markers.TE was used as a 
comparative method of measuring liver stiffness in this study and it demonstrated AUROC values 
consistent with findings reported in meta-analyses for predicting significant fibrosis (F≥2, AUROC 
= 0.88) and severe fibrosis (F≥3, AUROC = 0.91) (40). A limited number of studies have 
compared the diagnostic accuracy of LF index and serum fibrosis markers.  
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Limitations exist with our study. Firstly, this was an unblinded study performed in a wide group of 
unselected patients with varying aetiologies of chronic liver disease, introducing possible bias due 
to histologic differences of the varying etiologies of liver disease. However, most patients (>90%) 
had chronic viral hepatitis B or C. Further multicenter studies of larger patient cohorts, using a 
similar study design are needed to establish optimal cut-off values for each fibrosis stage and 
etiology. Secondly, the distribution of patients in our study was not equal through Ishak scores. 
We enrolled consecutive patients undergoing liver biopsy and the underlying distribution of 
patients reflects that normally observed in clinical practice. Finally, the same operators were used 
in the study and there was no patient control group. However, whilst each operator was aware 
that the patient had fibrosis, they were blinded to the pathological stage of the patient.  
In conclusion, the diagnostic performance of SE using RTE in this population was similar to other 
non-invasive tests for the assessment of significant liver fibrosis but inferior to TE in the 
assessment of severe fibrosis/cirrhosis in patients with suspected chronic liver disease.  
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Figures Legends 
Figure 1a. Real-time tissue elastogram from a 27 year-old male with hepatitis B viral hepatitis 
which demonstrates relative “soft” liver texture. The histological fibrosis stage is Ishak 1.  
Figure 1b. Real-time tissue elastogram from a 63 year-old female with hepatitis C viral hepatitis 
which demonstrates relative “hard” liver texture. The histological fibrosis stage is Ishak 6. 
Figure 2 Box and whisker plots of (a) liver fibrosis (LF) index, (b) TE, (c) APRI and (d) King’s 
Score according to different Ishak fibrosis stage. The length of the box represents the 
interquartile ranges (second and third quartiles) in which 50% of the values are located. Circles or 
stars represent outliers. The thick line through each box represents the median value. The error 
bars show the minimum and maximum values (range). Open circles and stars represent outliers.  
 
Figure 3 Comparison of the receiver operating characteristic curves of non-invasive methods for 
diagnosis of (a) significant fibrosis (Ishak ≥ stage 3) and (b) severe fibrosis/cirrhosis (Ishak ≥ 
stage 5) in patients with chronic liver disease in the study population 
 
